Fungating tumours in palliative care in adults (Guidelines)

Warning

Audience

  • Highland HSCP 
  • Primary and Secondary Care 

Fungating tumour

A fungating tumour is a primary or secondary cancer that has ulcerated the skin. The management of fungating tumours focuses on alleviating the distressing symptoms associated with the wound and providing emotional support to the patient and family/carers.  They most commonly develop from cancer of the head and neck, breast, melanoma and soft tissue sarcoma.  Treatment is directed towards control of bleeding, odour restriction, absorption of exudates, control of pain associated with the lesion and comfort/cosmetic appearance. This information is a guide and a comprehensive wound assessment should be undertaken.

If the wound is moist/dry and clean the primary dressing should be a non-adherent foam dressing (semi-permeable), see wound formulary

Pathway

Bleeding 
  • Haemostatic alginate dressing
  • Tranexamic acid topically. Soak gauze in 500mg/5mL injection ampoules and apply to wound. Can be left in-situ with dressing on top (unlicensed)
  • Adrenaline (epinephrine) topically. Soak gauze in adrenaline 1 in 1000 injection ampoules and apply to the wound for 10 minutes 
  • Sucralfate topically (for use after unsuccessful trial of adrenaline / tranexamic acid). Sucralfate paste (2 x 1g tablets crushed in 5mL of aqueous gel) or 2g/10mL suspension (unlicensed)
  • Further information. Scottish Palliative Care Guidelines - Bleeding
  • Radiotherapy 
  • Major haemorrhage. Scottish Palliative Care Guidelines - Bleeding Management  
  • Secondary dressing consists of foam dressing +/- additional padding and tubifast to secure 
  • For persistent symptoms contact Highland Hospice / PCAS
Odour control 
  • Metronidazole: oral 200mg to 400mg three times daily (unlicensed) or topical gel formulation twice a day, may be ongoing 
  • Metronidazole gel strength 0.75% (off-licence)
  • Charcoal dressing
  • Silver dressings. Not appropriate if radiotherapy is part of treatment plan 
  • Deodorisers in the room/use of aromatherapy oils 
  • Use of single room if appropriate 
Absorption of exudates 
  • Exclude wound infection as this can increase exudates 
  • Absorbent dressing, eg hydrogel / hydrofibre 
  • Control bacterial contamination 
  • Honey dressings 
  • Protect surrounding skin from excoriation and maceration with suitable barrier product
  • Surgical debridement
Pain 

Emotional support

The consequences of having a fungating lesion secondary to cancer can be far reaching and encompass physical, psychological, social, sexual and spiritual dimensions. Each patient will react in their own way and a sensitive, skilled approach to care is vital. Patients may experience depression, embarrassment, social isolation, fear, repulsion, shame, altered body image, and a constant reminder of advanced, incurable disease.

Health professionals need to establish trust with patients and family and use tact and sensitivity.

There are strategies for managing these psychosocial problems. Interventions should aim to boost patient confidence and improve their ability to socialise wherever possible.

  • cosmetic appearance – dressings need to effectively manage odour and exudates but where possible restore body symmetry
  • access to counselling services
  • appropriate social support decreases stress and anxiety at home
  • spiritual care according to individual’s beliefs
  • involvement of the patient, family and carers in decisions about care
  • open, honest communication of goals and decisions
  • appropriate use of touch/physical contact
  • access to complementary therapies.

Editorial Information

Last reviewed: 08/09/2023

Next review date: 30/09/2026

Author(s): Cancer Services .

Approved By: Approved TAMSG of the ATDC

Reviewer name(s): Lucy Dixon, Jeremy Keen, Gordon Linklater.

Document Id: TAM342

References

Further information for Patients

Self-management information